Dalton Pharma, Lehigh expand facilities; AMRI gets NIH grant; Akor, Aurobindo, Par recall products;

> Lehigh Valley Technologies in Allentown, PA, has received a $2.25 million state loan to help with a $5 million expansion that will allow it to add 52 new full-time jobs to its existing staff of 36. Story

> Dalton Pharma in North York, Ottawa, Canada, is getting a $2 million grant towards its $8.3 million expansion project, that will allow it to add to its 70-person workforce. Story

> AMRI ($AMRI) has gotten a $37.7 million, 10-year contract through the U.S. National Institute of Health Drug Manufacturing and Formulation Program (DMFP). Release

> Akorn ($AKRX) is recalling some of its triamcinolone acetonide lotion for failing impurities testing. Recall

> Aurobindo Pharma has recalled 24,816 bottles of gabapentin capsules after receiving complaints of empty capsules. Recall

> Par Pharmaceutical is recalling 38,788 bottles of hydralazine hydrochloride tablets after aluminum particles were found in some. Recall

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.